Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women

Cancer Research

Volumn 73, Issue 5, 2013, Pages 1502-1513

  Ladd, Jon J ^a   Chao, Timothy ^a   Johnson, Melissa M ^a   Qiu, Ji ^a   Chin, Alice ^a   Israel, Rebecca ^a   Pitteri, Sharon J ^a   Mao, Jianning ^b   Wu, Mei ^b   Amon, Lynn M ^a   McIntosh, Martin ^a   Li, Christopher ^b   Prentice, Ross ^a   Disis, Nora ^b   Hanash, Samir ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN; PROTEIN; PYROXYLIN; SPLICESOME PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CELL IMMORTALIZATION; CELL STRAIN MCF 7; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOREACTIVITY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; WESTERN BLOTTING;

AGED; ANIMALS; ANTIBODIES, NEOPLASM; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; AUTOANTIBODIES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLYCOLYSIS; HUMANS; MICE; MICE, TRANSGENIC; MIDDLE AGED; POSTMENOPAUSE; SPLICEOSOMES; TIME FACTORS;

EID: 84874845828     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2560     Document Type: Article

References (56)

1. Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res 2009;15:4733-41.
2. Goodell V, Disis ML. Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 2005;299:129-38.
3. Chapman C, Murray A, Chakrabarti J, Thorpe A, Woolston C, Sahin U, et al. Autoantibodies in breast cancer: Their use as an aid to early diagnosis. Ann Oncol 2007;18:868-73.
4. Anderson KS, Sibani S,Wallstrom G, Qiu J,Mendoza EA, Raphael J, et al. Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res 2011;10: 85-96.
5. Massoner P, Lueking A, Goehler H, Hopfner A, Kowald A, Kugler KG, et al. Serum-autoantibodies for discovery of prostate cancer specific biomarkers. Prostate 2012;72:427-36.
6. Babel I, Barderas R, Diaz-Uriarte R, Martinez-Torrecuadrada JL, Sanchez-Carbayo M, Casal JI. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009;8: 2382-95.
7. Tamesa MS, Kuramitsu Y, Fujimoto M, Maeda N, Nagashima Y, Tanaka T, et al. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis 2009;30:2168-81.
8. Chang W, Wu L, Cao F, Liu Y, Ma L, Wang M, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res 2011;17:5715-24.
9. Babel I, Barderas R, Diaz-Uriarte R, Moreno V, Suarez A, Fernandez-Acenero MJ, et al. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol Cell Proteomics 2011;10:M110.001784.
10. Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010;70:1306-13.
11. Madoz-Gurpide J, Kuick R, Wang H, Misek DE, Hanash SM. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics 2008; 7:268-81.
12. Pereira-Faca S, Qiu J, Krasnoselsky A, Newcomb L, Hanash S. Proteomic identification of tumor antigens in lung cancer. Mol Cell Proteomics 2005;4:S125-S.
13. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-6.
14. NamMJ, Kee MK, Kuick R, Hanash SM. Identification of defensin alpha 6 as a potential biomarker in colon adenocarcinoma. J Biol Chem 2005;280:8260-5.
15. Nam MJ, Madoz-Gurpide J, Wang H, Lescure P, Schmalbach CE, Zhao R, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: Occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003;3: 2108-15.
16. Bouwman K, Qiu J, Zhou HP, Schotanus M, Mangold LA, Vogt R, et al. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003;3:2200-7.
17. Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004;64:5504-10.
18. Amon LM, Pitteri SJ, Li CI, McIntosh MW, Ladd J, Disis ML, et al. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER breast cancer. Cancer Res 2012;72: 1935-42.
19. Wang H, Hanash S. Multi-dimensional liquid phase based separations in proteomics. J Chromatogr B-Analyt Technol Biomed Life Sci 2003;787:11-8.
20. Qiu J, Madoz-Gurpide J, Misek DE, Kuick R, Brenner DE, Michailidis G, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J Proteome Res 2004;3:261-7.
21. Wang H, Hanash SM. Increased throughput and reduced carryover of mass spectrometry-based proteomics using a high-efficiency nonsplit nanoflow parallel dual-columncapillaryHPLC system. J Proteome Res 2008;7:2743-55.
22. MacLean B, Eng JK, Beavis RC, McIntosh M. General framework for developing and evaluating database scoring algorithms using the TANDEM search engine. Bioinformatics 2006;22:2830-2.
23. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Analyt Chem 2003;75:4646-58.
24. Rauch A, Bellew M, Eng J, Fitzgibbon M, Holzman T, Hussey P, et al. Computational Proteomics Analysis System (CPAS): An extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 2006;5:112-21.
25. Arbuckle MR, Schilling AR, Harley JB, James JA. A limited lupus antispliceosomal response targets a cross-reactive, proline rich motif. J Autoimmun 1998;11:431-8.
26. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000;28:27-30.
27. Caporali R, Bugatti S, Bruschi E, Cavagna L, Montecucco C. Autoantibodies to heterogeneous nuclear ribonucleoproteins. Autoimmunity 2005;38:25-32.
28. Hardin JA, Thomas JO. Antibodies to histones in systemic lupuserythematosus-localization of prominent auto-antigens on histone-H1 and histone-H2b. P Natl Acad Sci Biol 1983;80:7410-4.
29. Kuo YB, Chang CA, Wu YK, Hsieh MJ, Tsai CH, Chen KT, et al. Identification and clinical association of anti-cytokeratin 18 autoantibody in COPD. Immunol Lett 2010;128:131-6.
30. Leidinger P, Keller A, Heisel S, Ludwig N, Rheinheimer S, Klein V, et al. Novel autoantigens immunogenic in COPD patients. Resp Res 2009;10:20.
31. Terrier B, Degand N, Guilpain P, Servettaz A, Guillevin L, Mouthon L. Alpha-enolase: A target of antibodies in infectious and autoimmune diseases. Autoimmun Rev 2007;6:176-82.
32. Hassfeld W, Steiner G, Studnickabenke A, Skriner K, Graninger W, Fischer I, et al. Autoimmune-response to the spliceosome-an immunological link between rheumatoid-arthritis, mixed connective-tissue disease, and systemic lupus-erythematosus. Arthritis Rheum 1995; 38:777-85.
33. Poole BD, Schneider RI, Guthridge JM, Velte CA, Reichlin M, Harley JB, et al. Early targets of nuclear RNP humoral autoimmunity in human systemic lupus erythematosus. Arthritis Rheum 2009;60:848-59.
34. Eggleton P, Ward FJ, Johnson S, Khamashta MA, Hughes GRV, Hajela VA, et al. Fine specificity of autoantibodies to calreticulin: Epitope mapping and characterization. Clin Exp Immunol 2000;120:384-91.
35. Katsumata Y, Kawaguchi Y, Baba S, Hattori S, Tahara K, Ito K, et al. Identification of three new autoantibodies associated with systemic lupus erythematosus using two proteomic approaches. Mol Cell Proteomics 2011;10:M110.005330.
36. Mandik-Nayak L, Allen PM. Initiation of an autoimmune response-insights from a transgenic model of rheumatoid arthritis. Immunol Res 2005;32:5-13.
37. Minota S, Jarjour WN, Suzuki N, Nojima Y, Roubey RAS, Mimura T, et al. Autoantibodies to nucleolin in systemic lupus-erythematosus and other diseases. J Immunol 1991;146:2249-52.
38. Skoldberg F, RonnblomL, Thornemo M, Lindahl A, Bird PI, Rorsman F, et al. Identification of AHNAK as a novel autoantigen in systemic lupus erythematosus. Biochem Biophys Res Commun 2002;291:951-8.
39. Takasaki Y, Kaneda K, Matsushita M, Yamada H, Nawata M, Matsudaira R, et al. Glyceraldehyde 3-phosphate dehydrogenase is a novel autoantigen leading autoimmune responses to proliferating cell nuclear antigen multiprotein complexes in lupus patients. Int Immunol 2004;16:1295-304.
40. Fossey SC, Vnencak-Jones CL, Olsen NJ, Sriram S, Garrison G, Deng XQ, et al. Identification of molecular biomarkers for multiple sclerosis. J Mol Diagn 2007;9:197-204.
41. Hauck SM, Dietter J, Kramer RL, Hofmaier F, Zipplies JK, Amann B, et al. Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol Cell Proteomics 2010;9:2292-305.
42. Huguet S, Labas V, Duclos-Vallee JC, Bruneel A, Vinh J, Samuel D, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 identified as an autoantigen in autoimmune hepatitis by proteome analysis. Proteomics 2004;4:1341-5.
43. Jastorff AM, Haegler K, Maccarrone G, Holsboer F, Weber F, Ziemssen T, et al. Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Proteomics Clin Appl 2009;3:1273-87.
44. Tahiri F, Le Naour F, Huguet S, Lai-Kuen R, Samuel D, Johanet C, et al. Identification of plasma membrane autoantigens in autoimmune hepatitis type 1 using a proteomics tool. Hepatology 2008;47:937-48.
45. Xiang Y, Sekine T, Nakamura H, Imajoh-Ohmi S, Fukuda H, Nishioka K, et al. Proteomic surveillance of autoimmunity in osteoarthritis: Identification of triosephosphate isomerase as an autoantigen in patients with osteoarthritis. Arthritis Rheum 2003;48:S292-S.
46. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumorassociated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008;7:1388-94.
47. Andre F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, et al. Exonic expression profiling of breast cancer and benign lesions: A retrospective analysis. Lancet Oncol 2009;10:381-90.
48. Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, Tai S, et al. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010;7:17-23.
49. Luqmani YA, Al Azmi A, Al Bader M, Abraham G, El Zawahri M. Modification of gene expression induced by siRNA targeting of estrogen receptor a in MCF7 human breast cancer cells. Int J Oncol 2009;34:231-42.
50. Ma YL, Peng JY, Zhang P, Huang L, Liu WJ, Shen TY, et al. Heterogeneous nuclear ribonucleoprotein A1 is identified as a potential biomarker for colorectal cancer based on differential proteomics technology. J Proteome Res 2009;8:4525-35.
51. Schiarea S, Salinas G, Allavena P, Scigliuolo GM, Bagnati R, Fanelli R, et al. Secretome analysis of multiple pancreatic cancer cell lines reveals perturbations of key functional networks. J Proteome Res 2010;9:4376-92.
52. Hatakeyama S, Sugihara K, Nakayama J, Akama TO, Wong SMA, Kawashima H, et al. Identification of mRNA splicing factors as the endothelial receptor for carbohydrate-dependent lung colonization of cancer cells. Proc Natl Acad Sci U S A 2009;106:3095-100.
53. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular-carcinoma and other malignancies. Am J Pathol 1992;140:859-70.
54. Backes C, Ludwig N, Leidinger P, Harz C, Hoffmann J, Keller A, et al. Immunogenicity of autoantigens. Bmc Genomics 2011;12:340.
55. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012;5:1036-43.
56. Clark CJ, Whang S, Paige KT. Incidence of precancerous lesions in breast reduction tissue: A pathologic review of 562 consecutive patients. Plast Reconstr Surg 2009;124:1033-9.